Want to see AU:CMB full AI Analyst Report?
CMB Stock Chart & Stats
AU$0.47
-AU$0.02(-4.44%)
At close: 4:00 PM EST
AU$0.47
-AU$0.02(-4.44%)
Day’s Range― - ―
52-Week RangeAU$0.34 - AU$0.60
Previous CloseN/A
Volume21.69K
Average Volume (3M)2.88K
Market Cap
AU$13.24M
Enterprise ValueAU$9.96M
Total Cash (Recent Filing)AU$1.12M
Total Debt (Recent Filing)AU$149.80K
Price to Earnings (P/E)―
Beta0.11
Next Earnings
Mar 04, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.25
Shares Outstanding29,431,917
10 Day Avg. Volume17
30 Day Avg. Volume2,880
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)4.31
Price to Sales (P/S)15.99
P/FCF Ratio-3.65
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance-sheet RecoveryThe move from negative equity to positive equity indicates a materially stronger capital base than in 2023. Maintaining positive equity through 2026 gives Regeneus more financial resilience while it continues developing and commercializing therapies, although ongoing losses remain a constraint.
Lower Debt BurdenDebt reduction lowers the company’s fixed financial obligations and can preserve more flexibility for research, clinical translation, and commercialization activities. The reduced leverage provides a stronger foundation than the prior year, even though cash burn may still require future funding.
Integrated Commercialization ModelRegeneus operates across the development path from regenerative-medicine research through clinical translation and commercialization. This integrated model can help align scientific work with potential product delivery and revenue generation, supporting a clearer long-term route from therapies to market.
Bears Say
Persistent Operating LossesRecurring operating losses show that the business has not yet established sustainable profitability. Continued negative EBIT can consume the capital base, limit internally funded investment, and increase dependence on external financing while therapies remain in development or commercialization.
Sustained Cash BurnPersistent negative operating and free cash flow means the company is not currently funding its activities through internally generated cash. If this pattern continues, Regeneus may need additional capital, creating funding and potential dilution risk over the medium term.
Volatile, Modest RevenueRevenue remains modest and highly uneven compared with the company’s development ambitions. The 2026 decline after the recent rebound suggests commercial traction is not yet consistent, making it harder to absorb operating costs or demonstrate a durable path to profitability.
Regeneus Ltd. News
CMB FAQ
What was Regeneus Ltd.’s price range in the past 12 months?
Regeneus Ltd. lowest share price was AU$0.34 and its highest was AU$0.60 in the past 12 months.
What is Regeneus Ltd.’s market cap?
Regeneus Ltd.’s market cap is AU$13.24M.
When is Regeneus Ltd.’s upcoming earnings report date?
Regeneus Ltd.’s upcoming earnings report date is Mar 04, 2027 which is in 134 days.
How were Regeneus Ltd.’s earnings last quarter?
Regeneus Ltd. released its earnings results on Aug 28, 2026. The company reported -AU$0.104 earnings per share for the quarter.
Is Regeneus Ltd. overvalued?
According to Wall Street analysts Regeneus Ltd.’s price is currently Overvalued.
Does Regeneus Ltd. pay dividends?
Regeneus Ltd. does not currently pay dividends.
What is Regeneus Ltd.’s EPS estimate?
Regeneus Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Regeneus Ltd. have?
Regeneus Ltd. has 29,431,917 shares outstanding.
What happened to Regeneus Ltd.’s price movement after its last earnings report?
Regeneus Ltd. reported an EPS of -AU$0.104 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Regeneus Ltd.?
Currently, no hedge funds are holding shares in AU:CMB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Regeneus Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-2.17%
12-Months-Change
Fundamentals
Return on Equity
-247.44%
Trailing 12-Months
Asset Growth
14.21%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Regeneus Ltd.
Cambium Bio Limited, a clinical-stage regenerative medicine company, focuses on developing biologics for ophthalmology and tissue repair applications. The company provides lead product candidate is Elate Ocular for the treatment of dry eye disease. The company also develops Progenza, a stem cell platform for knee osteoarthritis and other tissue repair indications; and Sygenus, for wound healing indications. Cambium Bio Limited is headquartered in Bella Vista, Australia.
Technical Analysis
Cynata Therapeutics Limited
―
Living Cell Technologies
―
Mesoblast Limited
―
Orthocell Ltd
―
Tissue Repair Ltd
―